SLC6A3 Protein

SLC6A3 Protein

Introduction

Pathway Diagram

```mermaid
flowchart TD
SLC6A3["SLC6A3<br/>(Dopamine Transporter)"]

DA_Reuptake["Dopamine Reuptake<br/>and Clearance"]
DA_Dysfunction["Dopaminergic<br/>Dysfunction"]

PD["Parkinson's Disease"]
AD["Alzheimer's Disease"]
ALS["Amyotrophic Lateral<br/>Sclerosis"]
HD["Huntington's Disease"]
MS["Multiple Sclerosis"]
Depression["Depression"]
Dementia["Dementia"]

SLC6A4["SLC6A4<br/>(Serotonin Transporter)"]
ABCB1["ABCB1<br/>(P-glycoprotein)"]
CYP3A4["CYP3A4<br/>(Drug Metabolism)"]

Epigenetic["Epigenetic<br/>Regulation"]
Therapeutic["Therapeutic<br/>Intervention"]

Neuroinflammation["Neuroinflammation"]
Motor_Deficits["Motor Deficits"]
Cognitive_Decline["Cognitive Decline"]

SLC6A3 -->|"regulates"| DA_Reuptake
DA_Reuptake -->|"dysfunction"| DA_Dysfunction

SLC6A3 -->|"activates"| PD
SLC6A3 -->|"protects_against"| PD
SLC6A3 -->|"associated_with"| AD
SLC6A3 -->|"activates"| ALS
SLC6A3 -->|"protects_against"| ALS
SLC6A3 -->|"associated_with"| HD
SLC6A3 -->|"regulates"| MS
SLC6A3 -->|"associated_with"| Depression
SLC6A3 -->|"therapeutic_target"| Dementia

DA_Dysfunction -->|"contributes_to"| Motor_Deficits
DA_Dysfunction -->|"leads_to"| Cognitive_Decline
DA_Dysfunction -->|"promotes"| Neuroinflammation

SLC6A3 -->|"interacts_with"| SLC6A4
SLC6A3 -->|"associated_with"| ABCB1
SLC6A3 -->|"associated_with"| CYP3A4

Epigenetic -->|"regulates"| SLC6A3

SLC6A3 Protein

Introduction

Pathway Diagram

Slc6A3 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Sodium/Dopamine Co-Transporter [@zahniser2004]

<div class="infobox infobox-protein"> [@vaughan2013]
<div class="infobox-header">SLC6A3 Protein</div> [@rudnick2006]
<div class="infobox-content"> [@de2009]
| Property | Value | [@khoshbouei2003]
|---------|-------| [@brooks2003]
| Protein Name | Sodium/Dopamine Co-Transporter | [@ciliax1999]
| Gene | SLC6A3 | [@bajaj2010]
| UniProt | Q01959 | [@giros1996]
| Molecular Weight | ~79 kDa | [@cook1995]
| Subcellular Localization | Plasma membrane (presynaptic terminals) |
| Protein Family | SLC6 (Na+/Cl- dependent neurotransmitter transporter) |
| Aliases | DAT, DAT1 |
</div>
</div>

Overview

The sodium/dopamine co-transporter (DAT), encoded by the SLC6A3 gene (also known as DAT1), is a critical membrane protein responsible for the reuptake of dopamine from the synaptic cleft back into presynaptic [neurons](/entities/neurons)[@gainetdinov2000]. This transporter is essential for maintaining dopamine homeostasis and terminating dopaminergic signaling in the nigrostriatal and mesolimbic pathways[@zahniser2004]. DAT is a major therapeutic target for Parkinson's disease, attention-deficit hyperactivity disorder (ADHD), and addiction disorders[@vaughan2013].

Structure

DAT belongs to the SLC6 family of Na+/Cl- dependent transporters, which share a common 12-transmembrane domain architecture[@rudnick2006]:

• Transmembrane domains 1-12: Form the translocation pore for dopamine
• Intracellular N-terminus: Contains regulatory sites for protein kinases
• Extracellular loop 2: Contains glycosylation sites important for membrane targeting
• Intracellular C-terminus: Contains phosphorylation sites and trafficking signals

Function in Dopamine Neurotransmission

Dopamine Reuptake

DAT is the primary mechanism for terminating dopaminergic signaling:

Regulation

DAT activity is regulated by multiple mechanisms[@khoshbouei2003]:

• Phosphorylation: PKC-mediated phosphorylation reduces transporter activity
• Protein kinase C (PKC): Activation leads to DAT internalization
• Calmodulin: Ca2+/calmodulin-dependent protein kinase regulates DAT trafficking
• Amphetamine: Reverses DAT function, causing dopamine release

Role in Parkinson's Disease

DAT Dysfunction in PD

Dopamine transporter dysfunction is central to Parkinson's disease pathogenesis[@brooks2003]:

• Reduced DAT binding: SPECT imaging shows decreased DAT binding in PD patients
• Early marker: DAT imaging detects presynaptic dopaminergic deficits before motor symptoms
• Disease progression: Declining DAT levels correlate with disease severity

DAT as Therapeutic Target

Multiple therapeutic strategies target DAT[@ciliax1999]:

| Strategy | Example | Mechanism |
|----------|---------|-----------|
| DAT inhibitors | Methylphenidate, bupropion | Block dopamine reuptake |
| Amphetamines | Levo-amphetamine | Reverse transport (release dopamine) |
| Gene therapy | AAV-DAT | Enhance dopamine reuptake capacity |

DAT Imaging in PD

DAT SPECT imaging (DaTscan) is FDA-approved for:[@bajaj2010]

• Differentiating Parkinsonian syndromes from essential tremor
• Detecting early presynaptic dopaminergic dysfunction
• Monitoring disease progression
• Assessing treatment response

Therapeutic Implications

Current Treatments

• Methylphenidate: Used for dopamine reuptake inhibition in PD
• Bupropion: Atypical antidepressant with DAT blocking activity
• Amantadine: Also affects DAT function

Investigational Therapies

• DAT modulators: Small molecules to enhance or restore DAT function
• Gene therapy: AAV-mediated DAT expression
• Neuroprotective agents: Drugs to prevent DAT degeneration

Disease Associations

| Disease | Association | Evidence |
|---------|-------------|----------|
| Parkinson's Disease | DAT deficiency | Reduced SPECT binding[@giros1996] |
| ADHD | SLC6A3 polymorphisms | Multiple genetic association studies[@cook1995] |
| Bipolar Disorder | DAT dysfunction | Imaging and genetic studies |
| Addiction | DAT polymorphisms | Reward pathway dysregulation |

Key Publications

See Also

• [DAT Protein](/proteins/dat-protein)
• [SLC6A3 Gene](/proteins/slc6a3-protein)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Dopamine Signaling](/mechanisms/dopamine-signaling)
• [VMAT2 Protein](/proteins/vmat2-protein)
• [Alpha-Synuclein](/proteins/alpha-synuclein)

Background

The study of Slc6A3 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [UniProt: Q01959](https://www.uniprot.org/uniprot/Q01959)
• [GeneCards: SLC6A3](https://www.genecards.org/cgi-bin/carddisp.pl?gene=SLC6A3)
• [OMIM: 126455](https://www.omim.org/entry/126455)

References